These benefits, along with a past report exhibiting that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like behavior in mice,2 support the concept of concentrating on ACKR3 as a novel way to modulate the opioid program, which could open new therapeutic avenues for opioid-similar disor